Corvus is the founding and majority shareholder of Conduit Pharmaceuticals, a clinical stage specialty biopharmaceutical company led by highly experienced pharmaceutical executives.
Corvus Capital is pleased to have advised Taylor Partners, the activist shareholder of East Imperial plc (LON: EISB), alongside Strand Hanson, on Taylor Partner's successful proposition to make a number of Board changes at EISB.
Corvus is the founding shareholder of Ebers Tech Inc., a private Canadian pharmaceutical company that utilises Co-crystallization and other technology to generate and monetize unique patented compounds and Intellectual Property around cannabinoids and psychedelics.
Corvus originated and negotiated Nuformix’s successful listing on the London Stock Exchange, by way of a Reverse Takeover by Levrett Plc, delivering 120x return for original investors.